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Abstract. 
 
The heregulin receptor tyrosine kinase 
ErbB-4 is constitutively cleaved, in the presence or ab-
sence of ligand, by an exofacial proteolytic activity pro-
ducing a membrane-anchored cytoplasmic domain 
fragment of 80 kD. Based on selective sensitivity to in-
hibitors, the proteolytic activity is identified as that of a 
metalloprotease. The 80-kD product is tyrosine phos-
phorylated and retains tyrosine kinase activity. Impor-
tantly, the levels of this fragment are controlled by pro-
teasome function. When proteasome activity is 
inhibited for 6 h, the kinase-active 80-kD ErbB-4 frag-
ment accumulates to a level equivalent to 60% of the 
initial amount of native ErbB-4 (
 
z
 
10
 
6
 
 receptors per 
cell). Hence, proteasome activity is essential to prevent 
the accumulation of a significant level of ligand-inde-
pendent, active ErbB-4 tyrosine kinase generated by 
metalloprotease activity. Proteasome activity, however, 
does not act on the native ErbB-4 receptor before the 
metalloprotease-mediated cleavage, as no ErbB-4 frag-
ments accumulate when metalloprotease activity is 
blocked. Although no ubiquitination of the native 
ErbB-4 is detected, the 80-kD fragment is polyubiquiti-
nated. The data, therefore, describe a unique pathway 
for the processing of growth factor receptors, which in-
volves the sequential function of an exofacial metallo-
protease and the cytoplasmic proteasome.
 
W
 
hen 
 
growth factor ligands bind to their cognate
receptors, tyrosine kinase activity is activated,
and results in the initiation of multiple signal
transduction pathways. Coincidentally, activated ligand–
receptor complexes are subject to less defined processes
that alter their activity and cell surface distribution, and/or
number. Most all ligand-occupied growth factor receptor
tyrosine kinases are rapidly internalized by receptor-medi-
ated endocytosis through clathrin-coated pits (Sorkin and
Waters, 1993). Tyrosine-kinase activity, as well as internal-
ization sequences in the receptor carboxyl terminus, are
essential for this step in receptor trafficking. Internalized
ligand–receptor complexes subsequently are sorted to ly-
sosomes where both receptor and ligand are degraded.
This process is thought to represent an attenuation mecha-
nism necessary for the proper biological response, as it
produces a dramatic decrease or downregulation in the
number of surface receptors. It has been reported that
growth factor binding to internalization-defective recep-
tors leads to increased transforming potential, presumably
due to persistent signaling at the cell surface (Wells et al.,
1990; Masui et al., 1991).
Within the ErbB family of receptor tyrosine kinases
(Earp et al., 1995), the activated EGF receptor or ErbB-1
is rapidly and extensively downregulated by this pathway
(Carpenter and Cohen, 1976). However, other members of
this family, which bind heregulin, are not subject to rapid
internalization and downregulation (Baulida et al., 1996;
Pinkas-Kramarski et al., 1996). This includes the two re-
ceptors, ErbB-3 and ErbB-4, which bind heregulin directly
(Plowman et al., 1993; Carraway et al., 1994; Tzahar et al.,
1994), as well as the ErbB-2/ErbB-3 heterodimer, which
also constitutes a high affinity heregulin receptor (Sliw-
kowski et al., 1994). As heregulin is not trafficked to the
internalization pathway by receptor-mediated endocyto-
sis, it seems likely that other mechanisms of receptor regu-
lation at the cell surface may control the function of these
receptors. A recent study found that protein kinase C acti-
vation brings about the rapid and extensive proteolytic
cleavage of ErbB-4, producing a soluble fragment (120 kD)
representing the extracellular ligand-binding domain and
a membrane-anchored fragment (80 kD) composed of the
entire cytoplasmic and transmembrane domain (Vecchi
et al., 1996).
This article focuses on a protein kinase C–independent
basal or constitutive mechanism that generates a similar
hydrolysis of ErbB-4. This hydrolysis is due to a metallo-
protease and produces an active tyrosine kinase, whose
levels are, in turn, controlled by proteasome activity.
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Materials and Methods
 
Materials
 
EGF was prepared from mouse submaxillary glands as previously de-
scribed (Savage and Cohen, 1972). Heregulin 
 
b
 
1 was a generous gift of M.
Sliwkowski (Genentech Inc., San Francisco, CA). Betacellulin, heparin-
binding EGF, and heregulin 
 
a
 
 were obtained from R & D Systems Inc.
(Minneapolis, MN). Neuregulin-2 was a gift from K. Carraway, III (Har-
vard Medical School, Cambridge, MA). Polyclonal IgG to the carboxyl
terminus (residues 1291–1308) of ErbB-4 were purchased from Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). Serum raised against the car-
boxyl-terminal sequence 1108–1264 of ErbB-4 was supplied by M. Kraus
(Instituto Europeo di Oncologia, Milan, Italy) (Vecchi et al., 1996). Anti-
sera to PLC-
 
g
 
1 was described previously (Arteaga et al., 1991). Anti-
phosphotyrosine purified IgG and HRP-conjugated protein A were pur-
chased from Zymed Labs, Inc., South San Franscisco, CA). Polyclonal
antibodies to Shc proteins were products of Transduction Laboratories
(Lexington, KY). Rabbit anti–ubiquitin serum, protein A–Sepharose, and
enhanced chemiluminescence (ECL)
 
1
 
 reagents were obtained from Sigma
Chemical Co. (St. Louis, MO). 
 
125
 
I-protein A was a product of ICN Bio-
medicals, Inc. (Irvine, CA) and Immunobilon-P membranes were from
MCI. PMA and wheat germ (WG) agarose were from Sigma Chemical
Co., bisindolylmaleimide (GF109203X) and 
 
N
 
-acetyl-
 
l
 
-leucinyl-
 
l
 
-leuci-
nyl-
 
l
 
-norleucinal (ALLN) were from Calbiochem-Novabiochem Corp.
(La Jolla, CA). The metalloprotease inhibitor BB-3103 was provided by
A. Drummond (British Biotech Pharmaceuticals Limited, Oxford, En-
gland). The metalloprotease inhibitors 
 
N
 
-(
 
dl
 
-[2-9{hydroxy-aminocarbo-
nyl}methyl]-4-methypentanoyl)-
 
l
 
-3-terbutyl-
 
l
 
-alanine, 2-aminoethylamide
(TAPI-2), and Batimastat (BB-94) were gifts of L. Matrisian and P.
Dempsey (Vanderbilt University, Nashville, TN). The proteasome inhibi-
tor lactacystin was purchased from J.E. Corey (Harvard University, Cam-
bridge, MA), and 
 
N
 
-carboxybenzyl-leucyl-leucyl-leucine (MG-132) and car-
boxybenzyl-leucyl-leucyl-leucine vinyl sulfone (Z-Leu3-VS) were gifts of S.
Cohen (Vanderbilt University, Nashville, TN; through H. Ploegh, Har-
vard University). PMA, metalloprotease inhibitors, and proteasome in-
hibitors ALLN, Z-leu3-VS, and MG-132 were dissolved in DMSO.
 
Cell Culture
 
T47-14 cells, transfected NIH 3T3 cells that overexpress human ErbB-4
(
 
z
 
10
 
6
 
 receptors per cell), have been described elsewhere (Baulida et al.,
1996; Vecchi et al., 1996). These cells were routinely grown in 5% CO
 
2
 
 at
37
 
8
 
C in DME containing 20 mM Hepes, pH 7.4, 50 
 
m
 
M Gentamycin
(GIBCO BRL, Grand Island, NY), and 10% calf serum. Atrial tumor myo-
cytes, AT-1 cells, derived from T antigen transgenic mice (Steinhelper et al.,
1990; Delcarpio et al., 1991), were provided by D.M. Roden (Vanderbilt
University). These cells, maintained as transplanted tumors, were pre-
pared and grown in culture as previously described (Yang et al., 1994).
Under these conditions, the cells maintain the phenotype properties of car-
diac myocytes (Yang and Roden, 1996; Lanson et al., 1992). Experimental
cultures were generally grown in 60- or 100-mm-diam culture dishes.
 
Immunoprecipitation and Immunoblotting
 
Cell lysates were obtained as previously described (Vecchi et al., 1996).
Briefly, after overnight starvation in DME and 0.5% serum, monolayers
were incubated for the indicated times at 37
 
8
 
C in basal medium (DME,
0.1% BSA, and 20 mM Hepes, pH 7.2) with indicated additions, i.e., inhib-
itors, growth factors. The cells were next washed with calcium and magne-
sium-free PBS and then solubilized for 20 min at 4
 
8
 
C in TGH buffer (1%
Triton X-100, 10% glycerol, 20 mM Hepes, pH 7.2, 100 mM NaCl, 1 mM
phenylmethylsulphonylfluoride, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin,
and 1 mM Na
 
3
 
VO
 
4
 
). Lysates were clarified by centrifugation (14,000 
 
g
 
, 10
min) at 4
 
8
 
C and protein concentration was determined by the modified
method of Bradford (Bio-Rad Laboratories, Hercules, CA). The ErbB-4
protein was immunoprecipitated by adding 
 
z
 
1 
 
m
 
g of ErbB-4 antibody per
200 
 
m
 
g of cell lysate for 2 h at 4
 
8
 
C and then incubating (1 h, 4
 
8
 
C) with pro-
tein A–Sepharose CL-4B. Subsequently, the immunocomplexes were ex-
tensively washed with TGH buffer and resuspended in 1
 
3
 
 Laemmli
buffer. After boiling, proteins in the samples were electrophoretically sep-
arated on 7.5% SDS-PAGE gels and transferred to nitrocellulose mem-
branes for Western blotting. Membranes were blocked with 5% milk in
PBS containing 0.05% Tween for 1 h before blotting with antibodies to
anti–ErbB-4, –Shc, –PLC-
 
g
 
1, and –ubiquitin. Before anti-phosphotyrosine
blotting, membranes were blocked by incubating for 1 h with 3% BSA in
TBST buffer (0.05% Tween, 150 mM NaCl, 50 mM Tris, pH 7.4). Mem-
branes were then incubated with the appropriate antibody for 2 h at room
temperature and washed with PBS or TBST buffer, incubated with 
 
125
 
I-
protein A for 1 h at room temperature, and after five washes with PBS or
TBST buffer, visualized by autoradiography (X-Omat AR film; Eastman
Kodak, Rochester, NY). Where indicated, bound antibody was detected
with HRP-protein A and ECL.
 
In Vitro Kinase Assay
 
T47-14 cells overexpressing ErbB-4 were washed and the cell monolayers
solubilized at 4
 
8
 
C in TGH buffer without Na
 
3
 
VO
 
4
 
. Equal aliquots of cell
lysates (100 
 
m
 
g protein) were immunoprecipitated by adding 0.5 
 
m
 
g of an-
tibody to ErbB-4. After a 2-h incubation at 4
 
8
 
C, protein A–Sepharose was
added for 1 h. The immunocomplexes were then washed twice with TGH
buffer without Na
 
3
 
VO
 
4
 
 and twice with kinase buffer (20 mM Hepes, pH
7.4, 3 mM MnCl
 
2
 
, 20 mM MgCl
 
2
 
, 50 mM NaCl, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml
leupeptin, and 100 
 
m
 
M Na
 
3
 
VO
 
4
 
). The immunocomplexes were resus-
pended in 50 
 
m
 
l of kinase buffer containing 20 
 
m
 
M cold ATP, and 4 
 
m
 
g of
recombinant PLC-
 
g
 
1 (Horstman et al., 1995) was added. The reaction
mixtures were then incubated at room temperature for the indicated times
before stopping the reaction by adding 50 
 
m
 
l of 2
 
3
 
 Laemmli buffer and
boiling for 5 min. Proteins were subsequently separated on a 7.5% SDS-
PAGE gel and analyzed for phosphotyrosine content by Western blotting
with antibody to phosphotyrosine. The amount of tyrosine phosphory-
lated PLC-
 
g
 
1 was quantitated by densitometric scanning. For each phos-
phorylation sample, a parallel aliquot of lysate was analyzed for ErbB-4
protein by immunoprecipitation and Western blot, as described above.
 
Lectin Fractionation
 
WG agarose was used to selectively adsorb the highly glycosylated native
ErbB-4 receptor, but did not react with the 80-kD ErbB-4 fragment ex-
pected to contain little, if any, carbohydrate. Lysates (100 
 
m
 
g) in TGH
buffer were incubated for 4 h at 4
 
8
 
C with 50 
 
m
 
l WG agarose (cross-linked
4% beads) that had been prewashed in TGH buffer. After incubation, the
mixture was centrifuged and the supernatant recovered. Anti–ErbB-4 was
added to the supernatant for analysis of kinase activity and ErbB-4 pro-
tein as described above. The WG agarose beads were also analyzed di-
rectly for adsorbed kinase activity and ErbB-4 protein.
 
Results
 
Metalloprotease Cleavage of ErbB-4
 
Previous data demonstrated a PMA-stimulated proteo-
lytic cleavage of ErbB-4, which produces a soluble extra-
cellular domain and a membrane-anchored fragment that
includes the tyrosine kinase cytoplasmic domain (Vecchi
et al., 1996). To identify the type of protease involved in
this cleavage, cells expressing ErbB-4 were preincubated
with various protease inhibitors before the addition of
PMA. The cleavage of ErbB-4 was then detected by assay-
ing the 80-kD cytoplasmic domain with anti–ErbB-4. The
results, shown in Table I, revealed that three metallopro-
tease inhibitors reduced the PMA-stimulated cleavage by
90%. Inhibitors of other types of proteases were relatively
ineffective in this assay. Hence, these data implicate a met-
alloprotease as the likely enzyme that modulates ErbB-4
structure in response to PMA. Previously, a low level of a
similarly sized cytoplasmic domain fragment was detected
in the absence of PMA (Vecchi et al., 1996). As the amount
of this 80-kD fragment constitutively released from ErbB-4
is small (
 
z
 
4%) relative to native ErbB-4 and PMA-stimu-
lated fragment levels (Table I), one cannot accurately
 
1. 
 
Abbreviations used in this paper
 
: ECL, enhanced chemiluminescence;
PLC-
 
g
 
1, phospholipase c-
 
g
 
1; WG, wheat germ. 
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judge inhibitor effects on the constitutive hydrolysis under
these conditions.
 
Proteasome Function in ErbB-4 Cleavage
 
Previous studies (Vecchi et al., 1996) showed that the
PMA-stimulated cleavage of ErbB-4 was independent of
heregulin binding. Various ErbB-4 ligands (including he-
regulin-
 
b
 
 and -
 
a
 
 isoforms, betacellulin, heparin-binding
EGF, and neuregulin-2), were assayed for their capacity to
alter the basal level of receptor cleavage. However, none
had a significant influence (data not shown).
However, when ErbB-4–expressing cells are exposed to
the proteasome inhibitors ALLN or lactacystin, the intra-
cellular level of the 80-kD ErbB-4 fragment is slowly but
dramatically increased (Fig. 1 
 
A
 
, lanes 
 
4–7
 
). The level of
accumulation of 80-kD fragment under these conditions
equals that previously reported (Vecchi et al., 1996) after
PMA treatment (Fig. 1, lane 
 
2
 
). Lactacystin is considered
the most specific inhibitor of proteasome activity (Fen-
teany et al., 1995). In addition, two peptide aldehyde pro-
teasome inhibitors, MG-132/Z-Leu 3-H and Z-Leu 3-Vs
(Bogyo et al., 1997) also enhanced accumulation of the 80-kD
fragment (data not shown). Hence, proteasome activity
normally limits the level of ErbB-4 80-kD fragment accu-
mulation. Additional experiments have shown that, simi-
lar to the 80-kD fragment generated in the presence of
PMA (Vecchi et al., 1996), the 80-kD fragment that accu-
mulates in the absence of proteasome function is tyrosine
phosphorylated (Fig. 1 
 
B
 
, lanes 
 
3–7
 
) and is membrane-
localized, as determined by cell fractionation (data not
shown).
To determine the rate and extent of this basal level of
ErbB-4 hydrolysis, the proteasome inhibitor ALLN was
added to stabilize the 80-kD fragment and accumulation
of the fragment was measured at various times thereafter.
As shown in Fig. 2 
 
A
 
, accumulation occurred slowly for
several hours, until 4–6 h when the amount of 80-kD frag-
ment was readily detectable. At this time, the cellular pool
of 80-kD ErbB-4 fragment was equal to 
 
z
 
60% of the ini-
tial level of native ErbB-4 receptor. Since the cells used in
this experiment overexpress ErbB-4 (
 
z
 
10
 
6
 
 receptors per
cell), it is estimated that the basal rate of ErbB-4 cleavage
is 
 
z
 
10
 
5
 
 receptors per hour. In a separate experiment, cells
were incubated with ALLN for 6 h to accumulate an 80-kD
ErbB-4 fragment. The ALLN was then removed by wash-
ing, which restores proteasome function within 60 min
(Rock et al., 1994), and the half-life of the 80-kD fragment
was determined (Fig. 2 
 
B
 
). Under these conditions, the
fragment was degraded with a half-life of 
 
z
 
4 h.
Ubiquitination is a frequent posttranslational marker
for proteasome substrates. Therefore, we used antibody to
ubiquitin to determine whether the 80-kD molecule is
modified in this manner. Cells were treated with PMA, he-
regulin, ALLN, or lactacystin for the indicated times and
then lysates were precipitated with antibody to the ErbB-4.
Subsequent Western blotting demonstrates the specific poly-
ubiquitination of the ErbB-4 fragment in cells treated with
ALLN or lactacystin (Fig. 3 
 
A
 
, lanes 
 
4
 
 and 
 
5
 
). Heteroge-
neous ubiquitinated products were detected from 80 kD to
the top of the gel. Using normal rabbit IgG, control pre-
cipitations of lysates from cells treated with proteosome
inhibitors showed that the detection of ubiquitinated pro-
teins is specific for anti–ErbB-4. Interestingly, no ubiquiti-
nation of the 80-kD ErbB-4 fragment generated by PMA
treatment was detected (Fig. 3 
 
A
 
, lane 
 
2
 
) even though
equivalent levels of 80-kD fragments were produced by
PMA, ALLN, and lactacystin (Fig. 3 
 
B
 
, lanes 
 
2
 
, 
 
4
 
, and 
 
5
 
).
Also, no ubiquitination of the native ErbB-4 receptor
could be detected in the absence or presence of heregulin
(Fig. 3 
 
A
 
, lanes 
 
1
 
 and 
 
3
 
). Addition of ALLN for 1 h also
failed to reveal the presence of ubiquitinated native recep-
tor (data not shown).
The results described above were obtained with NIH
 
Table I. Influence of Protease Inhibitors on ErbB-4 Proteolysis
 
Protease inhibitor Primary specificity 80-kD fragment (relative percent)
 
Control — 4
PMA (100 ng/ml) — 100
Phenylmethylsulfonylfluoride (2 mM) Serine proteases 66
Aprotinin (1.5 
 
m
 
M) Serine proteases 87
3,4-dichloroisocoumarin (2 mM) Serine proteases 77
E-64 (500 
 
m
 
M) Cysteine proteases 56
Leupeptin (105 
 
m
 
M) Trypsin, some cysteine proteases 81
Pepstatin (1 
 
m
 
M) Some aspartic proteases 92
 
N
 
-tosyl-
 
L
 
-phenylalanine chloromethyl ketone (100 
 
m
 
M) Chymotrypsin 131
 
N
 
-tosyl-
 
L
 
-lysyl chloromethyl ketone (100 
 
m
 
M) Trypsin 97
Elastatinal (100 
 
m
 
M) Elastase 102
EDTA (5 mM) Metalloproteases 104
EGTA (5 mM) Metalloproteases 135
BB-94 (1 
 
m
 
M) Metalloproteases 13
BB-94 (5 
 
m
 
M) Metalloproteases 5
BB-3103 (5 
 
m
 
M) Metalloproteases 24
BB-3103 (10 
 
m
 
M) Metalloproteases 10
TAPI-2 (10 
 
m
 
M) Metalloproteases 11
TAPI-2 (40 
 
m
 
M) Metalloproteases 4
 
Cells were preincubated with the indicated concentration of inhibitor for 20 min before the addition of PMA (100 ng/ml). After a 30-min incubation with PMA, the cells were
lysed and the amount of 80-kD ErbB-4 fragment quantitated as described in Materials and Methods. The amount of 80-kD fragment is expressed relative to what accumulated in
cells similarly treated with PMA only. 
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3T3 cells that overexpress the transfected ErbB-4 recep-
tor. To ascertain that the proteolytic activities toward
ErbB-4 are not a consequence of the exogenous expres-
sion of this receptor, AT-1 cardiac myocytes, which ex-
press endogenous ErbB-4, were assayed. As shown in Fig.
4, addition of PMA (lane 
 
8
 
), or the addition of proteasome
inhibitors (lanes 
 
2–7
 
) produced accumulation of an 80-kD
ErbB-4 fragment in these cells. It is probable that ErbB-4
is physiologically important in these cells, as targeted dis-
ruption of the ErbB-4 gene in mice produces, in null ho-
mozygotes, embryonic lethality due to abnormal heart de-
velopment (Gassmann et al., 1995).
 
Interrelationship of Metalloprotease and
Proteasome Functions
 
The results cited above suggest both metalloprotease and
proteasome activities are involved in a constitutive path-
way of ErbB-4 cleavage. However, these data only suggest
that the 80-kD fragment detected in the presence of pro-
teasome inhibitors represents accumulation of the metal-
loprotease cleavage product of ErbB-4. It is plausible that
the constitutive level of 80-kD ErbB-4 fragment is derived
from cleavage of native ErbB-4 by another protease or
splicing of ErbB-4 mRNA so as to produce an amino-ter-
minal truncation of the native protein. Therefore, we
tested whether the accumulation of 80-kD fragment in the
presence of a proteasome inhibitor depends on metallo-
protease activity.
As shown in Fig. 5 
 
A
 
, cells were pretreated with the met-
alloprotease inhibitor BB-94 for 30 min before the addi-
tion of the proteasome inhibitor ALLN for an additional 4 h.
The amount of 80-kD fragment was then compared to that
detected in cells treated for the same time with ALLN
only. The results show that inhibition of metalloprotease
activity reduces by 
 
z
 
80% the ALLN-dependent accumu-
lation of the 80-kD ErbB-4 fragment (Fig. 5, compare
lanes 
 
4
 
 and 5). This result indicates that the metallopro-
tease-generated 80-kD fragment is the substrate for pro-
teasome activity.
Although the PMA-stimulated accumulation of the 80-kD
ErbB-4 fragment is dependent on protein kinase C activity
(Vecchi et al., 1996), it is unclear whether the constitutive
hydrolysis may also depend on endogenous protein kinase
C activity. This has been tested by adding the specific pro-
tein kinase C inhibitor GF109203X to cells and then mea-
suring the accumulation of the fragment after the addition
of either PMA or ALLN. As shown in Fig. 5 B, the protein
kinase C inhibitor completely blocked the hydrolysis stim-
ulated by PMA (Fig. 5, lane 3) but had no influence on ac-
cumulation of the 80-kD fragment in the presence of
ALLN (Fig. 5, lane 5). This result indicates that the basal
level of ErbB-4 proteolysis is not dependent on protein ki-
nase C activity.
Tyrosine Kinase Activity of the 80-kD Fragment
The 80-kD ErbB-4 fragment that accumulates in the pres-
ence of proteasome inhibitors represents the entire cyto-
plasmic domain of ErbB-4 and may, therefore, retain ty-
rosine kinase activity. This possibility has been tested by
using in vitro kinase assays. After cell incubation in the ab-
sence or presence of ALLN, cell lysates were immunopre-
cipitated by antibody to the ErbB-4 carboxyl terminus.
The immunoprecipitates were then incubated with kinase
Figure 1. Detection of ErbB-4 fragment in the presence of pro-
teasome inhibitors. Cells were treated with PMA (100 ng/ml), he-
regulin (100 ng/ml), ALLN (250 mM), or lactacystin (10 mM) for
the indicated periods of time. After detergent lysis, duplicate ali-
quots (500 mg) of each lysate were immunoprecipitated with anti–
ErbB-4. After SDS-PAGE and transfer to nitrocellulose, the
samples were Western blotted with anti–ErbB-4 (A) or anti-
phosphotyrosine (B). Bound antibody was detected with 125I-pro-
tein A and visualized by autoradiography, as described in Materi-
als and Methods. Arrows indicate positions of the 180-kD native
ErbB-4 and 80-kD ErbB-4 fragment.
Figure 2. Time course of the
accumulation and metabolic
degradation of the 80-kD
ErbB-4 fragment. (A) Cells
were incubated at 378C in the
absence or presence of ALLN
(250  mM) for the indicated
periods of time. After deter-
gent solubilization, cell ly-
sates (100 mg) were analyzed
by SDS-PAGE and Western
blotting with anti–ErbB-4.
Immunoreactive native ErbB-4
(open circles) and the 80-kD
fragment (closed circles) were
visualized with 125I-protein A
autoradiography and quanti-
tated by PhosphorImager.
The amount of each molecule
is expressed relative to the
initial level of native ErbB-4
receptor in control cells at
time zero, which is set at 100%.
(B) Cells were incubated in
the absence or presence of
ALLN (250 mM) for 6 h at
378C to maximize the intracellular pool of 80-kD ErbB-4 frag-
ment. The cells were then washed once to remove ALLN and
incubated at 378C in media not containing the proteasome inhib-
itor. At the indicated times, cells were analyzed, as described
above, for the amount of 80-kD ErbB-4 fragment remaining. The
amount of fragment at each time point is expressed relative to
the amount present after the 6-h ALLN incubation (100%).Vecchi and Carpenter ErbB-4 Proteolysis 999
reaction components, including unlabeled ATP and re-
combinant tyrosine kinase substrate PLC-g1 (Horstman
et al., 1995). Phosphotyrosine blotting was used to detect
phosphorylated PLC-g1 and ErbB-4 blotting was used to
assess the levels of native ErbB-4 and the 80-kD ErbB-4
fragment. Control experiments showed that the ErbB-4
receptor is equally active in vitro regardless of whether the
cells are treated with or without heregulin (data not shown).
The results, shown in Fig. 6 A, indicate that the native
ErbB-4 (Fig. 6, lanes 3–5) and the ALLN-dependent 80-kD
ErbB-4 fragment (Fig. 6, lanes 6–8) phosphorylate PLC-g1
to an equivalent extent and at approximately the same
rate under these conditions. In this experiment, ErbB-4
blots (Fig. 6 B) show comparable levels of native ErbB-4
from control cells and 80-kD fragment from ALLN-
treated cells. Control assays showed that no kinase activity
was detected in the absence of ATP or when an unrelated
IgG was used for immunoprecipitation (Fig. 6, lanes 6–8).
After incubation in the presence of ATP, the 80-kD frag-
ment migrates at a slightly higher molecular mass indicative
of autophosphorylation (Fig. 6, lanes 6–8).
When lysates from ALLN-treated cells are immunopre-
cipitated with anti ErbB-4, a small amount of native ErbB-4
is detected together with the 80-kD fragment (Fig. 6 B).
Although the amount of native ErbB-4 in the ALLN sam-
ples is low, z20% of that in untreated cells, it is plausible
that it might significantly contribute to the observed phos-
phorylation activity in vitro. Two approaches have been
used to ascertain the possible contribution of native ErbB-4
to the kinase activity measured in immunoprecipitates
from ALLN-treated cells. First, to approximate the low
level of native ErbB-4 in ALLN lysates, control lysates were
diluted (1:3) to determine if that reduced level of receptor
is sufficient to phosphorylate PLC-g1 under these condi-
tions. As shown in Fig. 7, dilution did reduce by z75%
both the amount of native ErbB-4 (Fig. 7, lane 8) and the
kinase activity toward PLC-g1 (Fig. 7, lane 1) and does ap-
proximate the level of native ErbB-4 protein present in
immunoprecipitates of ALLN lysates (Fig. 7, compare
Figure 3. Ubiquitination of ErbB-4 Fragment. (A) Cells were in-
cubated for the indicated times with PMA (100 ng/ml), heregulin
(100 ng/ml), ALLN (250 mM), or lactacystin (50 mM). The cells
were then solubilized and lysates (1 mg each) were immunopre-
cipitated with anti-ErbB-4. After SDS-PAGE and transfer to ni-
trocellulose, each sample was blotted with anti-ubiquitin. Before
blotting, the nitrocellulose membranes were autoclaved in water
for 20 min to completely denature proteins (Lee et al., 1996;
Mimnaugh et al., 1996). Bound anti-ubiquitin was detected by ECL.
(B) Anti–ErbB-4 immunoprecipitated samples were stripped to
remove anti-ubiquitin and then reprobed with anti–ErbB-4.
Bound antibody was visualized with 125I-protein A. Arrows indi-
cate positions of the native ErbB-4 and 80-kD ErbB-4 fragment.
Figure 4. ErbB-4 degrada-
tion in cells endogenously ex-
pressing ErbB-4. Cardiac
myocytes (AT-1 cells) were
treated with vehicle alone
(control), ALLN (250 mM),
or lactacystin (10 mM) for the
indicated periods of time at
378C. Cell lysates (500 mg)
were then immunoprecipi-
tated with anti–ErbB-4 and
Western blotted with the
same antibody. Bound anti-
body was detected by ECL.
Arrows indicate positions of
native ErbB-4 and the 80-kD
ErbB-4 fragment.
Figure 5. Influence of metalloprotease or protein kinase C inhi-
bition on the accumulation of 80-kD ErbB-4 fragment in the ab-
sence of proteasome activity. (A) Cells were incubated at 378C
with vehicle alone (control), PMA (100 ng/ml) for 30 min, the
metalloprotease inhibitor BB-94 (1 mM) for 4.5 h, ALLN (250 mM)
for 4 h, or BB-94 and ALLN for 4.5 h. After cell solubilization, al-
iquots of cell lysate (100 mg) were separated by SDS-PAGE and
Western blotted with anti–ErbB-4. Bound antibody was visual-
ized by 125I-protein A and autoradiography. (B) Cells were incu-
bated with vehicle alone, PMA (100 ng/ml) for 30 min, ALLN
(250 mM) for 4 h, the protein kinase C inhibitor GF109203X (5 mM)
for 4.5 h, or GF109203X and ALLN for 4.5 h. Native ErbB-4 and
the 80-kD ErbB-4 fragment were detected as described in A. Ar-
rows indicate positions of the native ErbB-4 and 80-kD ErbB-4
fragment.The Journal of Cell Biology, Volume 139, 1997 1000
lanes  8 and 12). Nevertheless, this low level of native
ErbB-4 does contribute to the kinase activity measured in
ALLN lysates.
To measure the kinase activity of the 80-kD fragment
only, lysates from ALLN-treated cells were precleared with
WG lectin to adsorb the highly glycosylated native ErbB-4.
The 80-kD fragment is expected to contain little, if any,
carbohydrate. These WG supernatants were then immu-
noprecipitated with anti ErbB-4 and assayed for kinase ac-
tivity (Fig. 7 A) and ErbB-4 reactive protein (Fig. 7 B).
The results show that the 80-kD fragment retains phos-
phorylation activity in the absence of detectable native
ErbB-4 protein. WG agarose effectively removed, respec-
tively, the native ErbB-4 protein (Fig. 7, lane 10) and its in
vitro kinase activity (Fig. 7, lane 2) from control lysates.
The kinase activity (Fig. 7, lane 4) and protein (Fig. 7, lane
11) of the native ErbB-4 from the control lysates were re-
covered on the WG beads. Hence, WG fractionation ef-
fectively removes detectable levels of native ErbB-4 pro-
tein and kinase activity before immunoprecipitation.
When ALLN samples were precleared with WG aga-
rose, neither the amount of kinase activity (Fig. 7, lane 6)
nor 80-kD protein (Fig. 7, lane 13) was significantly de-
creased. In the WG agarose supernatant from the ALLN
lysate, the presence of even a small amount of native
ErbB-4 was no longer detectable (Fig. 7, compare lanes 12
and 13). The low level of native ErbB-4 kinase activity and
protein originally present in ALLN lysates was retained
on the WG agarose beads (Fig. 7, lanes 7 and 14). These
results demonstrate that the ErbB-4 80-kD fragment is, in
fact, an active tyrosine kinase. We have used densitomet-
ric scanning of the antiphosphotyrosine signal, represent-
ing PLC-g1 phosphorylation, and the anti–ErbB-4 signal,
indicating the level of ErbB-4 native or 80-kD fragment, to
approximate a kinase-specific activity. This analysis in-
cluded shorter exposures of the data shown in Figs. 6 and
7. In all samples, the specific phosphorylation activity of
the 80-kD fragment was equal to that of the native ErbB-4
receptor (data not shown).
Discussion
Numerous studies have demonstrated the ligand-depen-
dent degradation of growth factor receptors through a
mechanism involving internalization of coated pits and en-
dosome sorting to the lysosome (Sorkin and Waters,
1993). In certain instances, recycling of growth factor re-
Figure 6. Tyrosine phosphorylation activity in vitro of the native
ErbB-4 and 80-kD ErbB-4 fragment. Cells were incubated for 6 h
with or without ALLN (250 mM). After solubilization, replicate
aliquots (100 mg) of each lysate were precipitated with anti–
ErbB-4 and assayed for tyrosine kinase activity toward PLC-g1
by blotting with anti-phosphotyrosine (A), or the level of ErbB-4
protein by blotting with anti–ErbB-4 (B). Kinase assays were per-
formed as described in Materials and Methods with the incuba-
tion times in vitro as indicated. Control assays were performed
with extract from untreated cells and included an immunoprecip-
itation with an unrelated antibody (control IgG) or with ATP not
included in the kinase reaction (2ATP). Closed arrows indicate
positions of native ErbB-4 and the 80-kD ErbB-4 fragment,
whereas the open arrow indicates the position of tyrosine phos-
phorylated PLC-g1.
Figure 7. Separation of the native ErbB-4 and 80-kD ErbB-4
fragment by WG fractionation. Cells were left untreated (con-
trol) or incubated with ALLN (250 mM) for 6 h and solubilized as
described previously. After treatments of the lysates as indicated
below, samples were assayed for kinase activity toward PLC-g1
(A), or the amount of ErbB-4 protein (B). Lanes 2 and 5 indicate
the kinase activity recovered in ErbB-4 immunoprecipitates from
aliquots of control and ALLN lysates (100 mg), whereas lanes 9 and
12 demonstrate the amount of ErbB-4 protein (native or 80-kD)
present in immunoprecipitates from equivalent lysates (100 mg).
Lanes 1 and 8 show the amount of kinase activity and ErbB-4
protein detected when control lysates were diluted 1:3 before
precipitation with anti–ErbB-4. To test the capacity of WG aga-
rose to separate native ErbB-4 from the 80-kD ErbB-4 fragment,
aliquots (100 mg) of control and ALLN lysates were precleared
with WG agarose, as described in Materials and Methods. The
nonadsorbed supernatants were then precipitated with anti–
ErbB-4 before kinase assays (lanes 3 and 6), or detection of
ErbB-4 protein (lanes 10 and 13). Also, the amount of kinase ac-
tivity (lanes 4 and 7), and ErbB-4 protein (lanes 11 and 14) ad-
sorbed onto the WG agarose was measured. Solid arrows indicate
positions of native ErbB-4 and 80-kD ErbB-4 fragment. The
open arrow indicates tyrosine phosphorylated PLC-g1. Vecchi and Carpenter ErbB-4 Proteolysis 1001
ceptors and ligands from endosomes to the cell surface has
been noted. The cell surface ligand-dependent trafficking
of EGF receptor-like ErbB receptors is novel in that the
endocytic pathway is not used to rapidly internalize occu-
pied receptors after ligand binding (Baulida et al., 1996;
Pinkas-Kramarski et al., 1996). This may suggest alternate
mechanisms exist to desensitize these surface ligand–recep-
tor complexes as the mitogenic potency of EGF and hereg-
ulin are similar (Baulida et al., 1996).
A previous study has demonstrated that protein kinase
C activation rapidly produces a cleavage of the ErbB-4
ectodomain (Vecchi et al., 1996). The ectodomain cleavage
of several growth factor receptor tyrosine kinases has been
observed in cells treated with PMA (Downing et al., 1989;
Yee et al., 1993; Brizzi et al., 1994; Yee et al., 1994; O’Bryan
et al., 1995; Cabrera et al., 1996; Vecchi et al., 1996; Jeffers
et al., 1997); however, the PMA-sensitive protease(s) has
not been identified. Based on sensitivity to several metal-
loprotease inhibitors, we conclude that protein kinase C
activation directly or indirectly enhances the activity of a
member of this protease family toward the ErbB-4 extra-
cellular domain. Several reports indicate that PMA in-
creases expression of metalloprotease genes (Birkedal-
Hansen et al., 1993), but protein synthesis is not required
for the PMA-induced cleavage of ErbB-4 (Vecchi et al.,
1996). Hence, the action of protein kinase C in this system
is most likely at the secretion and/or activation step of the
metalloprotease latent precursor, known sites of regula-
tion (Coussens and Werb, 1996). However, the latter seems
unlikely given the intracellular localization of protein ki-
nase C and the extracellular location of metalloproteases,
which function mainly in the degradation of extracellular
matrix components. A transmembrane disintegrin mole-
cule could provide a means of communication, as recently
reported with the cleavage of tumor necrosis factor-a pre-
cursor (Black et al., 1997; Moss et al., 1997).
The data in this report show that a constitutive cleavage
of ErbB-4 also occurs in the absence of exogenous protein
kinase C activation and produces an 80-kD transmem-
brane and cytoplasmic domain fragment of ErbB-4 that is
very similar to the ErbB-4 fragment observed after PMA
addition to cells (Vecchi et al., 1996). Most likely this basal
receptor degradation represents a low level of metallopro-
tease activity in the extracellular environment. Although
this ErbB-4 fragment is generally found at low levels in the
cell, proteasome activity is crucial to prevent its accumula-
tion. Blocking proteasome activity with specific protea-
some inhibitors results in accumulation of this receptor
fragment to significant levels, approaching the cellular lev-
els of native ErbB-4. Since no ErbB-4 80-kD fragment ac-
cumulates in cells treated with both proteasome and met-
alloprotease inhibitors, the proteasome seems to degrade
the 80-kD fragment but not the intact ErbB-4 receptor.
This is reinforced by the finding that the 80-kD fragment is
ubiquitinated, but no ubiquitin is detectable on the intact
ErbB-4 molecule under several conditions including those
comparable to the detection of ubiquitin on the PDGF (Mori
et al., 1992; Yarden et al., 1986), EGF (Galcheva-Gargova
et al., 1995; Mori et al., 1995), stem cell factor/c-kit
(Miyazawa et al., 1994; Yee et al., 1994), and colony stimu-
lating factor-1/c-fms (Mori et al., 1995) receptor tyrosine
kinases. In each of these instances, however, ubiquitina-
tion occurred subsequent to growth factor binding. ErbB-4
receptor metabolism, therefore, represents a novel cou-
pling of two protease activities acting in series to allow
ligand-independent degradation of ErbB-4 and to prevent
accumulation of cytoplasmic domain receptor fragment.
If, in fact, the proteasome recognizes the 80-kD fragment
but not the intact ErbB-4 receptor, this implies that lack of
an extracellular domain in some way, perhaps involving
topological distribution, leads to recognition of the ErbB-4
cytoplasmic domain by the ubiquitination system.
Recently the hepatocyte growth factor receptor, Met,
has been shown to be ubiquitinated and subject to proteo-
some-mediated degradation in the absence or presence of
its ligand (Jeffers et al., 1997). In this system, prior cleav-
age of the intact receptor was not reported to be required
for ubiquitination. After proteasome inhibition a 50-kD
fragment of Met was detected that represented the cyto-
plasmic tyrosine kinase domain. Interestingly, PMA also
stimulated the accumulation of a similarly sized Met frag-
ment. In this system, however, the 50-kD fragment accu-
mulated to only a low level relative to the level of intact
Met. Phosphotyrosine was detectable on the 50-kD frag-
ment though kinase activity of the fragment was not as-
sayed given the low amount of fragment produced. Analo-
gously, PMA induces ectodomain cleavage of the NGF
receptor TrkA resulting in a tyrosine phosphorylated cyto-
plasmic domain fragment with unreported kinase activity
(Cabrera et al., 1996).
There are several reported instances where removal, by
proteolysis or deletion mutagenesis, of the ectodomain of
receptor tyrosine kinases has produced an active or acti-
vated kinase domain. This includes the insulin receptor
(Ellis et al., 1987; Goren et al., 1987; Wang et al., 1987;
Shoelson et al., 1988; Hsuan et al., 1989; Lebwohl et al.,
1991), insulin-like growth factor I receptor (Liu et al., 1992,
1993), and the Drosophila Sevenless receptor (Basler et al.,
1991). Oncogenic forms of the avian EGF receptor involve
deletion of the extracellular domain as well as other more
subtle changes, all of which contribute to its transforming
potential (Carter et al., 1994).
Using an in vitro assay with recombinant SH2 domain-
containing protein (PLC-g1) as a substrate, we have com-
pared the kinase activity of the 80-kD ErbB-4 fragment
accumulated in proteasome-inhibited cells to that of the
intact receptor recovered from control cells. The data
show that both molecules tyrosine phosphorylate PLC-g1
at comparable efficiencies. These data indicate that this
ErbB-4 fragment has intrinsic tyrosine kinase activity.
Therefore, it is possible that the fragment has ligand-inde-
pendent biological activity, increasing the importance of
proteasome degradation of the fragment. Unfortunately, it
is not possible to test the kinase activity of the 80-kD frag-
ment in intact cells due to its proteasome sensitivity and
the toxicity of proteosome inhibitors. Regardless of kinase
activity, the tyrosine phosphorylated fragment is constitu-
tively generated in ErbB-4-expressing cells and may act
not only as a kinase, but as a membrane-localized docking
molecule for signaling molecules with SH2 domains. Co-
precipitation data have shown the association of PLC-g1
and Shc with the 80-kD fragment produced in PMA-
treated cells (Vecchi et al., 1996). In some instances, dock-
ing at the cytoplasmic face of the plasma membrane mayThe Journal of Cell Biology, Volume 139, 1997 1002
be more critical than tyrosine phosphorylation for the
function of certain signaling molecules that associate with
receptor autophosphorylation sites, for example PI-3 ki-
nase and Grb-2 (Pawson and Schlessinger, 1993).
There are now examples of endogenous ectodomain
cleavage of several growth factor receptor tyrosine ki-
nases. If these results with ErbB-4 are generally applica-
ble, proteasome function may also limit the accumulation
of active tyrosine kinase fragments in other receptor sys-
tems.
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